THIS IS A CANCER OUTLIER.

Outliers are extremely rare patients who survive more than 5 years after diagnosis of lethal Cancers.

Cure51 unlocks these exceptional survivors’ secrets to eradicate Cancer within the next decade.

THESE ARE CANCER PATIENTS

THESE ARE CANCER PATIENTS

SCROLL TO EXPLORE

SCROLL TO EXPLORE

SCROLL TO EXPLORE

UNTIL ALL SURVIVE.

We believe in a world where Cancer Outliers become the blueprint for curing everyone because miracles should happen to all.

Cure51 is co-founded with worldwide leading oncology centers

1

1

LEADING
PARTNERS

1+

1+

CENTERS

1

1

COUNTRIES

0k+

0k+

PATIENTS

WE ARE A TECH-BIO COMPANY

SURVIVORS DATA ARE OUR COMPASS TOWARDS SUCCESS OF NOVEL ONCOLOGY DRUG PROGRAMS.

We have set up one of the largest Cancer network in history, covering every continent, and have successfully established collaboration with the world's leading Cancer centers.

We have set up one of the largest Cancer network in history, covering every continent, and have successfully established collaboration with the world's leading Cancer centers.

Our computational biology team works with our scientific partners to discover multimodal signatures and create a library of robust targets contributing to the design of best-in-class drugs.

Our computational biology team works with our scientific partners to discover multimodal signatures and create a library of robust targets contributing to the design of best-in-class drugs.

We develop precision medicine tools in order to deliver actionable insights to discover novel therapeutics.

We develop precision medicine tools in order to deliver actionable insights to discover novel therapeutics.

WE ARE A TECH- BIO COMPANY

SURVIVORS DATA ARE OUR COMPASS TOWARDS SUCCESS OF NOVEL ONCOLOGY DRUG PROGRAMS.

We have built one of the largest Cancer network in history, across all continents and managed to bring to our captable 3 leading Cancer centers in the world.

We have built one of the largest Cancer network in history, across all continents and managed to bring to our captable 3 leading Cancer centers in the world.

Our computational biology team works with our scientific partners to discover multimodal signatures and create a library of robust targets contributing to the design of best-in-class drugs.

Our computational biology team works with our scientific partners to discover multimodal signatures and create a library of robust targets contributing to the design of best-in-class drugs.

We develop precision medicine tools in order to deliver actionable insights to discover novel therapeutics.

We develop precision medicine tools in order to deliver actionable insights to discover novel therapeutics.

OUR MISSION

WE IDENTIFY AND COLLECT UNIQUE DATA FROM THOUSANDS OF long-term cancer SURVIVORS. 

Oncology players usually look at the biology

of the 99% of the patients who die from the most lethal Cancers.

At Cure51, we are focusing on exceptional Cancer survivors from across all continents, to build a unique clinical and multi-omics database and contribute to Cancer eradication.

At Cure 51, we are focusing on Cancer survivors from across all continents to build a unique clinical and multi-omics database and contribute to Cancer eradication.

WE IDENTIFY AND COLLECT UNIQUE DATA FROM THOUSANDS OF long-term cancer SURVIVORS. 

Oncology players usually look at the biology

of the 99% of the patients who die from the most lethal Cancers.

At Cure51, we are focusing on exceptional Cancer survivors from across all continents, to build a unique clinical and multi-omics database and contribute to Cancer eradication.

Cure51 focuses on extraordinary patients.

the Exception

that proves

the rule.

Our exceptional survivor community is a living proof that nature can beat Cancer.

Camille, USA

Camille, USA

Jean-Luc, France

Jean-Luc, France

Yann, France

Yann, France

Samantha, USA

Samantha, USA

Maria, Chile

Maria, Chile

Guillaume, France

Guillaume, France

Catherine, France

Catherine, France

OUR NETWORK

THE COLLECTIVE WILL SHAPE THE CURE

Healing

takes much
more than a village.

→ Building

1

1

Cohorts of patients

→ Targeting a community of

1

1

Cohorts of patients

→ Building

1

1

Cohorts of patients

→ Building

1

1

Cohorts of patients

→ Analyzing

1

1

omics modalities

→ Partnering

1

1

omics modalities

→ Analyzing

1

1

omics modalities

→ Analyzing

10

10

omics modalities

→ Collaborating with

1

1

BEST-IN-CLASS LABS

→ Collaborating with

1

1

BEST-IN-CLASS LABS

→ Collaborating with

1

1

BEST-IN-CLASS LABS

→ Collaborating with

1

1

BEST-IN-CLASS LABS

→ Bringing together

0

0

Nationalities

→ Co-fonded with

0

0

Nationalities

→ Bringing together

0

0

Nationalities

→ Co-founded with

0

0

Nationalities

→ Building a team of

+6

+6

Talents

→ Building a team of

+6

+6

Talents

→ Building a team of

+6

+6

Talents

→ Building a team of

+6

+6

Talents

→ Speaking

1

1

Languages

→ Speaking

1

1

Languages

→ Speaking

1

1

Languages

→ Speaking

1

1

Languages

OUR SCIENTIFIC LEADERS

Our Scientific Steering Committee
includes world-renowned oncologists

  • JOSEP TABERNERO, MD, PhD

    Director Vall d’Hebron Institute of Oncology, Barcelona

    FABRICE ANDRÉ, MD, PhD

    President Elect ESMO Research Director Institut Gustave Roussy, Villejuif

    OLIVIER ELEMENTO, PhD

    Director of Englander Institute for Precision Medicine at Cornell University, NY

    LOUIS DE MESTIER, MD

    Principal Investigator Hopital Beaujon, AP-HP, Paris

    PAN-CHYR YANG, MD, PhD

    Principal Investigator National Taiwan University Hospital (NTUH)

    NELSON DUSETTI, PhD

    Research Director, INSERM | Pancreatic Cancer & Translational Oncology

    SCOTT KOPETZ, MD

    Head of Colorectal Cancer Moonshot programs MD Anderson, Houston

    SOLANGE PETERS, MD, PhD

    Head of Medical Oncology CHUV Lausanne

    ULRICH KEILHOLZ, MD, PhD

    LEAD SCLC, Director Charité Comprehensive Cancer Center Berlin

    JEAN-YVES BLAY, MD, PhD

    President UniCancer & Director Centre Léon Bérard, Lyon

Contact us